期刊文献+

临床试验效应值的分析和解释 被引量:5

How to Analyze and Interpret the Effective Values in Clinical Trials
暂未订购
导出
摘要 临床试验效应值的分析应包括效应值大小和精度两个方面,而对试验效应的解释应遵循准确、清晰和定量的原则。对于主要临床结局,可使用相对危险度、比数比、相对危险度降低率、绝对危险度降低率、减少1例重大临床事件需要治疗的人数等指标;而替代指标和中间指标的解释方法仍需要加强研究。国内中医药研究中的试验效应表达尚有很多问题有待解决。 The analysis of the effective value obtained in clinical trails should take account of both sides of its size and precision, for its interpretation, the general principles of: accuracy, explicitness and quantification should be complied. Criteria such as relative risk (RR), relative risk reducing rate (RRR), absolute risk reducing rate (ARR) and number needed to treat (NNT) an important clinical event, etc. are commonly used in the primary outcomes interpretation, while the methods to express the effective size and precision of surrogate outcomes and intermediary outcomes are needed to be further studied. Many problems for give expression to the outcome of TCM clinical trail still remain to be solved.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2005年第8期677-681,共5页 Chinese Journal of Integrated Traditional and Western Medicine
基金 广东省科技厅资助的循证医学方法研究(No.2KM05801s)
关键词 临床试验 效应值 中医药 疗效评价 试验效应 临床结局 相对危险度降低 绝对危险度降低 中医药研究 临床事件 clinical trial effective value traditional Chinese medicine outcome assessment
  • 相关文献

参考文献10

  • 1郭新峰,朱泉,赖世隆.替代指标和中间指标及其在中医药疗效评价研究中应用价值的思考[J].中国中西医结合杂志,2005,25(7):585-590. 被引量:58
  • 2徐天和 田考聪.中国医学统计百科全书—描述性统计分册[M].北京:人民卫生出版社,2004.37.
  • 3David L, Sackett R, Brian Haynes, et al. Clinical epidemiology-A basic science for clinical medicine. 2nd ed. Little:Brown and Company, 1991:203.
  • 4MitchellH Katz著.式变量分析临床实用指南[M].北京:中国科学技术出版社,2000.818-850.
  • 5Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310(6977): 452-454.
  • 6Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature: Ⅱ . How to use an article about therapy or prevention: B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271(9):703-707.
  • 7Guyatt GH, Naylor CD, Juniper E, et al. Users' guides to the medical literature. Ⅻ. How to use articles about healthrelated quality of life. AJMA 1997;277(15):1232-1237.
  • 8Sprangers MA, Cull A, Bjordal K, et al. The European organization for research and treatment of cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC study group on quality of life. Qual Life Res 1993;2(4):287-295.
  • 9Kelvin J, Bie NO, Peter C. Mastering statistics a guide for health service professionals and researchers. United Kingdom:Stanley Thornes (Publishers) Ltd, 109-113.
  • 10BernardRosner著.生物统计学基础[M].北京:科学出版社,2004.554-563.

二级参考文献19

  • 1Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA.1999 ;282(8): 786-790.
  • 2Johnston K. What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 1999; 18(4): 167-173.
  • 3The Cochrance Reviewer' Handbook Glossary (Version 4.1.4), 26-27. The Cochrane Collaboration 2001.
  • 4Chuang-Stein C, DeMasi R. Surrogate endpoints in AIDS drug development: current status. Drug Information J 1998;32: 439-448, 457-459.
  • 5Gould AL. Discussion of "Surrogate endpoints in AIDS drug evelopment: current status" by C. Chuang-Stein and Ralph DeMasi. Drug Information J 1998 ;32: 453-456.
  • 6Hill AM, DeMasi R, Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther 1998 ;3(3) :139-145.
  • 7Ellenberg SS. Commentary on "Surrogate endpoints in AIDS drug development: current status"by C. chuang-stein and R.DeMasi. Drug Information J 1998;32:453-456.
  • 8Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
  • 9Echt DS, Leibson PR, Mitchel LB, et al. Cardiac arrhythmia suppression trial. N Engl J Med. 1989 ;321:406.
  • 10Fleming TR, De Mets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med, 1996; 125 (7):605-613.

共引文献57

同被引文献183

引证文献5

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部